for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

UCB SA

UCB.BR

Latest Trade

79.96EUR

Change

1.10(+1.39%)

Volume

260,887

Today's Range

78.94

 - 

79.98

52 Week Range

62.26

 - 

80.74

As of on the Euronext Brussels ∙ Minimum 15 minute delay

Latest Developments

UCB Raises FY Guidance, Expects Now Revenue of About EUR 4.9 Bln

Jan 10 (Reuters) - Ucb SA <UCB.BR>::UCB UPDATES ITS FINANCIAL OUTLOOK FOR 2019.UCB SA - STRONGER THAN EXPECTED NET SALES LEAD TO HIGHER EARNINGS LEVEL IN 2019.UCB SA - TOTAL REVENUE IN 2019 ARE EXPECTED TO REACH APPROX. € 4.9BN – PREVIOUS OUTLOOK WAS IN THE RANGE OF € 4.6 – 4.7BLN.UCB SA - UNDERLYING PROFITABILITY (RECURRING EBITDA) IS NOW EXPECTED AT LEAST AT UPPER END OF RANGE OF 27% - 29% OF REVENUE - PREVIOUS GUIDANCE WAS IN RANGE OF 27% - 29%.UCB SA - CORE EPS 2019 ARE NOW EXPECTED TO BE HIGHER THAN EUR 4.80 - PREVIOUS RANGE WAS EUR 4.40 - 4.80.UCB SA - CORE EPS ARE NOW EXPECTED TO BE HIGHER THAN € 4.80 FOR 2019.UCB SA - 2019 UNDERLYING PROFITABILITY (RECURRING EBITDA) IS NOW EXPECTED AT LEAST AT THE UPPER END OF THE RANGE OF 27% - 29% OF REVENUE - PREVIOUS GUIDANCE WAS IN THE RANGE OF 27% – 29%.UCB SA - THESE CHANGES ARE DRIVEN BY BETTER THAN EXPECTED NET SALES, DUE TO STRONG DEMAND FOR CIMZIA® AND VIMPAT® IN THE FOURTH QUARTER 2019. TO OPTIMIZE THE GROWTH OPPORTUNITY ADDITIONAL MARKETING ACTIVITIES WERE FUNDED.

UCB To Build New Biotech Manufacturing Plant In Belgium

Dec 18 (Reuters) - Ucb SA <UCB.BR>::UCB TO BUILD NEW BIOTECH MANUFACTURING PLANT IN BELGIUM.CONSTRUCTION IS DUE TO START IN Q1 OF 2020.NEW FACILITY, REPRESENTING AN INVESTMENT OF MORE THAN 300 MILLION EUROS OVER COMING YEARS, IS EXPECTED TO BE OPERATIONAL IN 2024.UCB IS EXPECTING TO CREATE MORE THAN 150 NEW, HIGH SKILLED JOBS ONCE PLANT BECOMES FULLY OPERATIONAL.

UCB Presents Final Results from Phase II Study of Rozanolixizumab

Dec 9 (Reuters) - Ucb SA <UCB.BR>::UCB PRESENTS FINAL RESULTS FROM PHASE II STUDY OF ROZANOLIXIZUMAB IN PRIMARY IMMUNE THROMBOCYTOPENIA (ITP).PHASE II DATA DEMONSTRATE THAT ROZANOLIXIZUMAB WAS WELL TOLERATED BY PATIENTS WITH PRIMARY ITP ACROSS ALL DOSE GROUPS.SAFETY, TOLERABILITY AND EFFICACY DATA SUPPORT PHASE III DEVELOPMENT OF ROZANOLIXIZUMAB FOR PRIMARY ITP.

UCB Announces Positive Results From The Phase 3 Active-Controlled Be Sure Study

Dec 6 (Reuters) - Ucb SA <UCB.BR>::BIMEKIZUMAB PHASE 3 PSORIASIS STUDY DEMONSTRATES SUPERIORITY VERSUS HUMIRA.UCB WILL SUBMIT APPLICATIONS TO REGULATORY AUTHORITIES FOR APPROVAL OF BIMEKIZUMAB TO TREAT ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN MID-2020.BE SURE IS THIRD PHASE 3 BIMEKIZUMAB PSORIASIS STUDY TO REPORT POSITIVE RESULTS SINCE OCTOBER.BE SURE STUDY, COMPARING BIMEKIZUMAB TO HUMIRA® (ADALIMUMAB) FOR THE TREATMENT OF ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS, MET ALL CO-PRIMARY AND RANKED SECONDARY ENDPOINTS.FIRST TOP-LINE RESULTS EXPECTED BY END OF 2021.

UCB Announces Positive Results For Bimekizumab In Second Phase 3 Psoriasis Study

Nov 15 (Reuters) - UCB SA <UCB.BR>::BIMEKIZUMAB POSITIVE RESULTS CONFIRMED IN SECOND PHASE 3 PSORIASIS STUDY.PHASE 3 BE READY STUDY MET ALL PRIMARY AND RANKED SECONDARY ENDPOINTS.PLANS TO SUBMIT APPLICATIONS TO REGULATORY AUTHORITIES FOR APPROVAL OF BIMEKIZUMAB TO TREAT ADULTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS IN MID-2020.

Amgen Says Evenity® (Romosozumab) Receives Positive CHMP Opinion For Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture

Oct 18 (Reuters) - Amgen Inc <AMGN.O>::EVENITY® (ROMOSOZUMAB) RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF SEVERE OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT HIGH RISK OF FRACTURE.

Ra Pharmaceuticals - If Deal Is Terminated, Co May Be Required To Pay UCB S.A. A Termination Fee Of $75 Mln In Cash

Oct 10 (Reuters) - Ra Pharmaceuticals Inc <RARX.O>::RA PHARMACEUTICALS - IF DEAL IS TERMINATED UNDER CERTAIN CIRCUMSTANCES, CO MAY BE REQUIRED TO PAY UCB S.A. A TERMINATION FEE OF $75 MILLION IN CASH.

UCB Agrees To Acquire Ra Pharmaceuticals For 2.1 Billion Dollars

Oct 10 (Reuters) - UCB SA <UCB.BR>::UCB AGREES TO ACQUIRE RA PHARMACEUTICALS.JOINING FORCES TO IMPROVE TREATMENT OPTIONS FOR PEOPLE LIVING WITH MYASTHENIA GRAVIS AND OTHER RARE DISEASES.ACQUISITION WILL NOT IMPACT UCB'S 2019 FINANCIAL GUIDANCE.ACQUISITION WILL ENABLE ACCELERATED TOP AND BOTTOM LINE GROWTH FROM 2024 ONWARDS.TOTAL TRANSACTION VALUE OF AROUND US$ 2.1 BILLION / € 2.0 BILLION (NET OF RA PHARMA CASH) BASED ON US$ 48 IN CASH PER RA PHARMACEUTICALS SHARE (APPROXIMATELY US$ 2.5BN / € 2.2BN).DEAL WOULD BE DILUTIVE TO UCB'S MID-TERM EARNINGS LEVEL.DEAL WOULD MOVE MID-TERM TARGET OF UCB REACHING A REBITDA RATIO (TO REVENUE) OF 31% TO 2022 FROM 2021 AS PREVIOUSLY GUIDED.UCB AND RA PHARMA EXPECT TO COMPLETE TRANSACTION BY END OF Q1 2020.

UCB H1 Revenue Up At 2.3 Billion Euros

July 25 (Reuters) - UCB SA <UCB.BR>::H1 VIMPAT NET SALES EUR 622 MILLION VERSUS EUR 522 MILLION YEAR AGO.UCB HALF YEAR REPORT 2019: UCB'S STRONG PERFORMANCE ENABLES CONTINUED INVESTMENT INTO FUTURE GROWTH DRIVERS.H1 REVENUE REACHED EUR 2.3 BILLION (+2%, +4% CER(1)).H1 CIMZIA NET SALES EUR 782 MILLION VERSUS EUR 679 MILLION YEAR AGO.H1 UNDERLYING PROFITABILITY (REBITDA(3)) WAS EUR 724 MILLION (-9%, -1% CER) OR A RATIO OF 31%.FINANCIAL OUTLOOK FOR 2019 CONFIRMED.H1 KEPPRA NET SALE EUR 371 MILLION VERSUS EUR 392 MILLION YEAR AGO.H1 BRIVIACT NET SALES EUR 103 MILLION VERSUS EUR 60 MILLION YEAR AGO.H1 NEUPRO NET SALES EUR 158 MILLION VERSUS EUR 148 MILLION YEAR AGO.CFO TRANSITION IN 2020.CHIEF FINANCIAL OFFICER, DETLEF THIELGEN, WILL BE TRANSITIONING OUT WITHIN A YEAR FROM NOW. A SEARCH FOR A SUCCESSOR HAS JUST BEGUN..H1 VIMPAT NET SALES EUR 622 MILLION VERSUS EUR 522 MILLION YEAR AGO.

UCB H1 Net Sales Increased To 2.2 Billion Euros

July 25 (Reuters) - UCB SA <UCB.BR>::UCB HALF YEAR REPORT 2019: UCB'S STRONG PERFORMANCE ENABLES CONTINUED INVESTMENT INTO FUTURE GROWTH DRIVERS.H1 REVENUE REACHED EUR 2.3 BILLION (+2%, +4% CER(1)).H1 CIMZIA NET SALES EUR 782 MILLION VERSUS EUR 679 MILLION YEAR AGO.H1 UNDERLYING PROFITABILITY (REBITDA(3)) WAS EUR 724 MILLION (-9%, -1% CER) OR A RATIO OF 31%.H1 VIMPAT NET SALES EUR 371 MILLION VERSUS EUR 522 MILLION YEAR AGO.FINANCIAL OUTLOOK FOR 2019 CONFIRMED.H1 VIMPAT NET SALES EUR 622 MILLION VERSUS EUR 522 MILLION YEAR AGO.H1 KEPPRA NET SALE EUR 371 MILLION VERSUS EUR 392 MILLION YEAR AGO.H1 BRIVIACT NET SALES EUR 103 MILLION VERSUS EUR 60 MILLION YEAR AGO.H1 NEUPRO NET SALES EUR 158 MILLION VERSUS EUR 148 MILLION YEAR AGO.H1 REBITDA EUR 724 MILLION VERSUS EUR 794 MILLION YEAR AGO.OUTLOOK 2019 CONFIRMED.CFO TRANSITION IN 2020.CHIEF FINANCIAL OFFICER, DETLEF THIELGEN, WILL BE TRANSITIONING OUT WITHIN A YEAR FROM NOW. A SEARCH FOR A SUCCESSOR HAS JUST BEGUN..

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up